Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3 Abstract #1668

Introduction: The classification of lung neuroendocrine neoplasms (Lung-NENs) according to the WHO classification 2010 for GEP-NENs, including a provisional category for Lung-NET G3 with Ki67 >20%, may have prognostic implications.
Aim(s): The prognostic impact of WHO2010 classification including the NET G3 category was investigated in Lung-NENs.
Materials and methods: 213 surgically resected Lung-NENs from Japan were histopathologically re-evaluated and the data correlated with survival.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: Lung NEN

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2198 PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung
Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Atsuko Kasajima
Keywords: Lung NEN, PD-L1, Prognosis
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#2952 Genomic Landscape of Neuroendocrine Neoplasms from Gastrointestinal Tract, Pancreas, Lung, Rare and Unknown Primary Locations
Introduction: There are still few large-scale sequencing data to depict the genomic landscape of neuroendocrine neoplasms (NEN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Professor Jie Chen
Authors: Chen L, Liu M, Zhang Y, Guo Y, ...
#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites
Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Jerome Cros
Authors: Mamodaly M, Chen R, Cazes A, Guedj N, ...
#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, ...